Search Results 341-350 of 18002 for Alopecia

  1. Head and neck cancers - Doctors and departments - Mayo Clinic

    This designation recognizes the institution's scientific excellence and multidisciplinary resources focused on cancer prevention, diagnosis and treatment.

  2. A Study to Assess the Safety and Dose Escalation of Pegtomarginase (PT01) for Subjects with Advanced Malignancies - Mayo Clinic

    03) except for subjects with alopecia; subjects receiving luteinizing hormone-releasing hormone agonists may be considered for enrollment after discussion with ...

  3. Testing The Use Of The Combination Of Selumetinib And Olaparib Or Selumetinib Alone Targeted Treatment For RAS Pathway Mutant Recurrent Or Persistent Ovarian And Endometrial Cancers, A ComboMATCH Treatment Trial - Mayo Clinic

    ... alopecia - Patients with uncontrolled intercurrent illness - Patients with >= grade 2 neuropathy within 14 days of registration - Patients with severe ...

  4. A Study to Evaluate Durvalumab plus Topotecan or Lurbinectedin in Patients with Small Cell Lung Cancer - Mayo Clinic

    Exceptions: Neuropathy, fatigue, and/or alopecia may be grade 1. Known active central nervous system (CNS) metastases. NOTE: Patients with previously ...

  5. Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working - Mayo Clinic

    (which must be ≤ grade 2), alopecia and/or endocrinopathies related to prior immunotherapy which are controlled with hormone replacement. - Patients must ...

  6. Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer - Mayo Clinic

    ... alopecia) and/or in whom ≥30% of the bone marrow was irradiated. Patient has had major surgery ≤14 days prior to registration or has not recovered from ...

  7. Testing the Addition of an Anti-cancer Drug, ASTX727, to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer - Mayo Clinic

    - Patients who have recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1) with the exception of alopecia.

  8. Clinical trials - Oncology (Medical)

    Natural History Evaluation Among Female Breast Cancer Survivors with Endocrine Therapy-Induced Alopecia. Rochester, Minn., Mankato, Minn., Albert Lea, Minn ...

  9. A Study to Evaluate Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC - Mayo Clinic

    Subjects with vitiligo or alopecia;; Subjects with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement;; Any chronic skin ...

  10. Head and neck cancers - Doctors and departments - Mayo Clinic

    ... Alopecia areata, Melasma. Show more areas of focus for Ashley B. Wentworth, M.D.. Josh P. Wiedermann, M.D.. Otolaryngologist. Rochester ...